| P2093 | author name string | A Kang | |
| | T Todo | |
| | I K Kim | |
| | S C Jordan | |
| | N N Nissen | |
| | A S Klein | |
| | A Vo | |
| | V Sundaram | |
| | A Annamalai | |
| | S-H Pan | |
| | J A Steggerda | |
| P2860 | cites work | Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch. | Q51016759 |
| | Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. | Q51936605 |
| | Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. | Q55034268 |
| | Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation | Q57134890 |
| | Reversal of transplantation immunity by liver grafting | Q59075507 |
| | Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells | Q70067993 |
| | The natural history of azathioprine compliance after renal transplantation | Q74566883 |
| | Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg) | Q74815832 |
| | Combined liver-kidney transplantation in patients with cirrhosis and renal failure: effect of a positive cross-match and benefits of combined transplantation | Q77182437 |
| | Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year | Q83659526 |
| | Acute humoral rejection in an ABO compatible combined liver-kidney transplant--the kidney is not always protected | Q84065061 |
| | Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization | Q86568728 |
| | Adherence to medication after liver transplantation in Scotland: a pilot study | Q94481178 |
| | Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation | Q34124202 |
| | Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies | Q34205519 |
| | Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial | Q34373536 |
| | Identification of patients best suited for combined liver-kidney transplantation: part II. | Q34575149 |
| | The role of donor-specific HLA alloantibodies in liver transplantation | Q35547041 |
| | Class II alloantibody and mortality in simultaneous liver-kidney transplantation | Q35547071 |
| | Indications for combined liver and kidney transplantation: propositions after a 23-yr experience | Q37650993 |
| | Clinical relevance of human leukocyte antigen antibodies in liver, heart, lung and intestine transplantation | Q38120400 |
| | Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 |
| | Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). | Q42598124 |
| | Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation | Q43181339 |
| | Outcome of simultaneous liver-kidney transplantation in highly sensitized, crossmatch-positive patients | Q44577632 |
| | Self-reported non-adherence to immune-suppressant therapy in liver transplant recipients: demographic, interpersonal, and intrapersonal factors | Q44583771 |
| | Incidence of renal and liver rejection and patient survival rate following combined liver and kidney transplantation. | Q45035165 |
| | Blood group A isoagglutinins in A(2) → O simultaneous liver/kidney transplantation may not influence kidney function | Q45036002 |
| | Combined liver-kidney transplants: allosensitization and recipient outcomes | Q45329810 |
| | Successful deceased-donor kidney transplantation in crossmatch-positive patients with peritransplant plasma exchange and Rituximab | Q46084219 |
| | Rituximab and intravenous immune globulin for desensitization during renal transplantation | Q46477840 |
| | Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? | Q47880758 |
| | Simultaneous liver-kidney transplantation: evaluation to decision making. | Q50158149 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1394-1401 | |
| P577 | publication date | 2017-07-01 | |
| P1433 | published in | Transplantation Proceedings | Q7834825 |
| P1476 | title | Outcomes of Highly Sensitized Patients Undergoing Simultaneous Liver and Kidney Transplantation: A Single-Center Experience With Desensitization | |
| P478 | volume | 49 | |